机构：[1]Centre for Molecular Oncology, Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ, UK[2]Department of Epidemiology, Second Military Medical University, Shanghai, 200433, China[3]Department of Molecular and Genetic Toxicology, The Key Laboratory of Modern Toxicology, School of Public Health, Nanjing Medical University, Nanjing, 210029, China[4]Department of Urology, Wuxi Second People’s Hospital, Nanjing Medical University, Wuxi, 214002, China[5]Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China江苏省人民医院[6]Department of Urology, The First Affiliated Hospital, Chongqing Medical University, Chongqing, 400016, China重庆医科大学附属第一医院[7]Department of Urology, Zhongshan Hospital, Fudan University Medical College, Shanghai, 200032, China[8]Liaoning People’s Hospital and Center of Experiment and Technology, China Medical University, Shenyang, 110001, China[9]Program for Personalized Cancer Care, North Shore University Health System, Evanston, IL 60201, U.S.A[10]Fudan Institute of Urology, Huashang Hospital, Fudan University, Shanghai, 200040, China[11]Department of Urology, Tongji Hospital, Huazhong Science and Technology University, Wuhan, 430030, China华中科技大学同济医学院附属同济医院[12]Department of Urology, Xiehe Hospital, Huazhong Science and Technology University, Wuhan, 430022, China[13]Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China[14]Department of Pathology, The First Affiliated Hospital, Zhejiang University Medical College, Hangzhou, 310009, China浙江大学医学院附属第一医院[15]Department of Pathology, Changhai Hospital, The Second Military Medical University, Shanghai, 200433, China[16]Department of Urology, First Affiliated Hospital, Medical College, Zhengzhou University, Zhengzhou, 450003, China[17]Department of Urology, North Sichuan Medical College, Nanchong, 637000, China[18]Department of Nutrition Science, Shenyang Medical College, Shenyang, 110034, China[19]Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge- Strangeways Research Laboratory, Cambridge, CB1 8RN, UK[20]Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK[21]Division of Genetics and Epidemiology, The Institute of Cancer Research, London, SM2 5NG, UK[22]Department of Urology, Changzheng Hospital, The Second Military Medical University, Shanghai, 200003, China[23]Department of Urology, Changhai Hospital, The Second Military Medical University, Shanghai, 200433, China[24]Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China[25]The Royal Marsden NHS Foundation Trust, London and Surrey, SM2 5NG, UK
Prostate cancer predisposition has been extensively investigated in European populations, but there have been few studies of other ethnic groups. To investigate prostate cancer susceptibility in the under-investigated Chinese population, we performed single-nucleotide polymorphism (SNP) array analysis on a cohort of Chinese cases and controls and then meta-analysis with data from the existing Chinese prostate cancer genome-wide association study (GWAS). Genotyping 211,155 SNPs in 495 cases and 640 controls of Chinese ancestry identified several new suggestive Chinese prostate cancer predisposition loci. However, none of them reached genome-wide significance level either by meta-analysis or replication study. The meta-analysis with the Chinese GWAS data revealed that four 8q24 loci are the main contributors to Chinese prostate cancer risk and the risk alleles from three of them exist at much higher frequencies in Chinese than European populations. We also found that several predisposition loci reported in Western populations have different effect on Chinese men. Therefore, this first extensive single-nucleotide polymorphism study of Chinese prostate cancer in comparison with European population indicates that four loci on 8q24 contribute to a great risk of prostate cancer in a considerable large proportion of Chinese men. Based on those four loci, the top 10% of the population have six-or two-fold prostate cancer risk compared with men of the bottom 10% or median risk respectively, which may facilitate the design of prostate cancer genetic risk screening and prevention in Chinese men. These findings also provide additional insights into the etiology and pathogenesis of prostate cancer.
基金：
This work was also supported by National Natural Science foundation of China for funding support to H Zhang (Grant No: 30671793 and 81072377), N Feng (Grant No: 81272831), X Zhang (Grant No: 30572139, 30872924 and 81072095), S Zhao (Grant No: 81072092 and 81328017), Y Yu (Grant No: 81172448) and Program for New Century Excellent Talents in University from Department of Education of China (NCET-08-0223) and the National High Technology Research and Development Program of China (863 Program 2012AA021101) to X Zhang.
第一作者机构：[1]Centre for Molecular Oncology, Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ, UK
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Jacek Marzec,Xueying Mao,Meiling Li,et al.A genetic study and meta-analysis of the genetic predisposition of prostate cancer in a Chinese population[J].ONCOTARGET.2016,7(16):21393-21403.doi:10.18632/oncotarget.7250.
APA：
Jacek Marzec,Xueying Mao,Meiling Li,Meilin Wang,Ninghan Feng...&The CHIPGECS Group.(2016).A genetic study and meta-analysis of the genetic predisposition of prostate cancer in a Chinese population.ONCOTARGET,7,(16)
MLA：
Jacek Marzec,et al."A genetic study and meta-analysis of the genetic predisposition of prostate cancer in a Chinese population".ONCOTARGET 7..16(2016):21393-21403
医学